June 2017
Lundi |
|
|
Contact : yann.leverrier@inserm.fr mathias.faure@inserm.fr
|
Lundi 11h00
Salle Condorcet
Séminaire Externe |
« Toward understanding how biological clocks drive sleep » | |
![]() |
Steven BROWN (University of Zurich)
Host: Kiran Padmanabhan .
|
Lundi 11h00
Salle Condorcet
Séminaire Externe
|
« The complex evolutionary history of brown algal sex Chromosomes » | |
|
Susana COELHO . (Station Biologique deRoscoff,CNRS) host: Nicolas Goudemand |
Mardi 11h00
IBCP Conférence |
" Chill life's machinery under the microscope: visualization of viruses and enzymes by cryoEM " | ||
|
|
Lundi 11h00
Amphi Mérieux
Séminaire externe
|
Immunotherapies & Innovations for Infectious Diseases Congress 2019 | |
|
https://i4id.org/ We are proud to welcome you to the third edition of the Immunotherapies & Innovations for Infectious Diseases Congress (I4ID2019), that will be held in Lyon, France on December 4-5, 2019.
The purpose of this two-day congress is to foster interactions between pharmaceutical industries, research labs, service providers, technology developers, and clinicians, thus contribute to the development of innovative strategies against infectious diseases in a multidisciplinary approach. I4ID2019, follows the success of the first two editions, I4ID2017 & I4ID2018, that counted with the presence of more than 330 participants from different countries representing more than 160+ organizations and 60 internationally renowned speakers that have exchanged on immunotherapy as a new therapeutic approach to fight infectious diseases. For this year edition I4ID2019, the congress will address immunotherapies for infectious diseases as well as highlight complementary innovative approaches. The Scientific Committee has set-up a stimulating program focusing on therapeutic strategies, diagnosis and epidemiology to fight infectious diseases and tackle the issue of antimicrobial multi-resistance. The program will in particular propose talks on immunotherapy, phagotherapy, microbiota, new antimicrobials, diagnosis tools, biomarkers, epidemiology, NGS strategies, real-time follow up and the use of artificial intelligence (AI) in these fields. The I4ID2019 includes keynote lectures, pitch talks of new innovative projects, industrial talks from pharmaceutical companies and poster presentations. Moreover, there will be several opportunities for networking, companies to showcase their new products and technologies as well as dedicated time for business partnering, through an online B2B platform. . |
Mardi 11h00
Salle des Thèses CRC
Séminaire externe |
“ 6ème journée nationale de recherche en rhumatologie pédiatrique ” | |
![]() |
contact : Alexandre Belot |
Lundç 11h00
|
|
|||
|
|
Mardi 11h00
Salle des Thèses CRC
Séminaire externe |
Regulation of T-cell immunity and tolerance to cancer by the NF-kB family of transcription factors ” | ||
|
Cancer progression is greatly influenced by a delicate balance between immunity and tolerance to tumors. While effector T cells (Teff) function to destroy tumor cells, their regulatory T cell (Treg) counterparts are powerful inhibitors of anti-tumor activity. The recent success of immunotherapies demonstrates that this balance can be shifted effectively towards enhanced anti-tumor immunity, to delay or even stop cancer progression. However, only a fraction of patients respond to these treatments. Understanding the molecular mechanisms that drive these responses therefore has important implications for the development of improved therapies. We have recently highlighted the selective contributions of NF-kappaB subunits in Treg function during cancer. Genetic and chemical inhibition of NF-kB c-Rel, but not RelA, impaired Treg homeostasis and delayed cancer growth in mouse models, highlighting c-Rel as a promising therapeutic target. Intriguingly, we recently observed that RelA is essential in the function of mouse and human Teff cells in the steady-state and during cancer. Our work provides novel insights in the molecular regulation of immunity and tolerance to cancer, and paves the way to NF-kB subunits-specific targeting therapies. |
Mercredi 11h00
Amphi Pasteur |
« Partitioning the genome via chromatin looping and phase separation » | |
|
Giorgio Trinchieri (Director of the Cancer and Inflammation Program (CIP)
Center for Cancer Research, NCI, NIH Bethesda, Maryland - USA) contact : uzma.hasan@inserm.fr
Commensal microorganisms colonize barrier surfaces of all multicellular organisms, including those of humans. For more than 500 million years commensal microorganisms and their hosts have coevolved and adapted to each other. As a result, the commensal microbiota affects many immune and non-immune functions of their hosts, and de facto the two together comprise one metaorganism. The commensal microbiota communicates with the host via biologically active molecules. Recently, it has been reported that microbial imbalance may play a critical role in the development of multiple diseases, such as cancer, autoimmune conditions and increased susceptibility to infection. The commensal microbiota not only may affect the development, progression and immune evasion of cancer but it has also important effects on the response to cancer immune- and chemo-therapy. Myeloid cells are a major component of the tumor microenvironment where they play a dual role inducing anti-tumor immune responses but mostly promoting immune evasion, tumor progression and metastases formation. Myeloid cells respond to environmental factors including signals derived from |